Filip, S <br/><br/>
The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.  [electronic resource] 

 -  Neoplasma  1999 
 - 166-72 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0028-2685 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Blood Transfusion<br/>Breast Neoplasms--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>Drug Therapy, Combination<br/>Epirubicin--administration & dosage<br/>Erythropoietin--adverse effects<br/>Female<br/>Granulocyte Colony-Stimulating Factor--adverse effects<br/>Hematopoiesis--drug effects<br/>Hematopoietic Stem Cell Mobilization<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Leukapheresis<br/>Leukocyte Count--drug effects<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Patient Selection<br/>Recombinant Proteins